Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cells

Journal of Immunology

Volumn 180, Issue 11, 2008, Pages 7287-7293

  Van Der Vliet, Hans J J ^a,b   Wang, Ruojie ^a   Yue, Simon C ^a   Koon, Henry B ^a   Balk, Steven P ^a   Exley, Mark A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; CD1 ANTIGEN; CYTOKINE;

ADVANCED CANCER; ARTICLE; BONE MARROW CELL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ADULT; AGED; CELL LINE; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD1; CELL LINE; CYTOKINES; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTE SUBSETS; TRANSFORMING GROWTH FACTOR BETA;

EID: 47249109791     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.11.7287     Document Type: Article

References (39)

1. Kronenberg, M., and A. Rudensky. 2005. Regulation of immunity by self-reactive T cells. Nature 435: 598-604.
2. van der Vliet, H. J., J. W. Moiling, B. M. von Blomberg, N. Nishi, W. Kolgen, A. J. van den Eertwegh, H. M. Pinedo, G. Giaccone, and R. J. Scheper. 2004. The immunoregulatory role of CDld-restricted natural killer T cells in disease. Clin. Immunol. 112: 8-23.
3. van der Vliet, H. J., S. P. Balk, and M. A. Exley. 2006. Natural killer T cell-based cancer immunotherapy. Clin. Cancer Res. 12: 5921-5923.
4. Swann, J. B., J. M. Coquet, M. J. Smyth, and D. I. Godfrey. 2007. CDl-restricted T cells and tumor immunity. Curr. Top. Microbiol. Immunol. 314: 293-323.
5. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol. Rev. 220: 183-198.
6. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
7. + natural killer T cells of healthy volunteers and cancer patients using α-galactosylceram-ide-Ioaded and environmentally instructed dendritic cells. Cancer Res. 63: 4101-4106.
8. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116: 87-93.
9. Tahir, S. M., O. Cheng, A. Shaulov, Y. Koezuka, G. J. Bubley, S. B. Wilson, S. P. Balk, and M. A. Exley. 2001. Loss of IFN-7 production by invariant NK T cells in advanced cancer. J. Immunol. 167: 4046-4050.
10. Dhodapkar, M. V., M. D. Geller, D. H. Chang, K. Shimizu, S. Fujii, K. M. Dhodapkar, and J. Krasovsky. 2003. A reversible defect in natural killer T cell function characterizes the progression of pre-malignant to malignant multiple myeloma. J. Exp. Med. 197: 1667-1676.
11. Tachibana, T., H. Onodera, T. Tsuruyama, A. Mori, S. Nagayama, H. Hiai, and M. Imamura. 2005. Increased intratumor Vα 24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11: 7322-7327.
12. Moiling, J. W., J. A. Langius, J. A. Langendijk, C. R. Leemans, H. J. Bonkes, H. J. van der Vliet, B. M. von Blomberg, R. J. Scheper, and A. J. van den Eertwegh. 2007. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J. Clin. Oncol. 25: 862-868.
13. Metelitsa, L. S., H. W. Wu, H. Wang, Y. Yang. Z. Warsi, S. Ashqharzadeh, S. Groshen, S. B. Wilson, and R. C. Seeger. 2004. Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J. Exp. Med. 199: 1213-1221.
14. Shaulov, A., S. Yue, R. J. Wang, R. M. Joyce, S. P. Balk, H. T. Kim, D. E. Avigan, L. Uhl, R. Sackstein, and M. A. Exley. 2008. Peripheral blood progenitor cell product contains Thl-biased noninvariant CDld-reactive natural killer T cells: implications for posttransplant survival. Exp. Hematol. 36: 464-472.
15. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
16. Hoffman, T. K., J. Muller-Berghaus, R. L. Ferris, J. T. Johnson, W. J. Storkus, and T. L. Whiteside. 2002. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 8: 1787-1793.
17. Yanagimoto, H., S. Takai, S. Satoi, H. Toyokawa, K. Takahashi, N. Terakawa, A. H. Kwon, and Y. Kamiyama. 2005. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin. Immunol. 114: 52-60.
18. Yue, S. C., A. Shaulov, R. Wang, S. P. Balk, and M. A. Exley. 2005. CDld ligation on human monocytes directly signals rapid NF-kB activation and production of bioactive IL-12. Proc. Nail Acad. Sci. USA 102: 11811-11816.
19. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J. Immunol. 163: 93-101.
20. Kitamura, H., K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. van Kaer, et al. 1999. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med. 189: 1121-1128.
21. Camaud, C, D. Lee, O. Donnars, S. H. Park, A. Beavis, Y. Koezuka, and A. Bendelac. 1999. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163: 4647-4650.
22. Eberl, G., and H. R. MacDonald. 2000. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 39: 985-992.
23. van der Vliet, H. J., H. B. Koon, S. C. Yue, B. Uzunparmak, V. Seery, M. A. Gavin, A. Y. Rudensky, M. B. Atkins, S. P. Balk, and M. A. Exley. 2007. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13: 2100-2108.
24. Dzionek, A., A. Fuchs, P. Schmidt, S. Cremer, M. Zysk, S. Miltenyi, D. W. Buck, and J. Schmitz. 2000. BDCA-2. BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165: 6037-6046.
25. + NKT cell numbers and dendritic cell CD Id expression in hepatitis C virus infected patients. Clin. Immunol. 114: 183-189.
26. Hayakawa, Y., K. Takeda, H. Yagita, L. van Kaer, I. Saiki, and K. Okumura. 2001. Differential regulation of Thl and Th2 functions of NKT cells by CD28 and CD40 coslimulatory pathways. J. Immunol. 166: 6012-6018.
27. Trapani, J. A. 2005. The dual adverse effects of TGF-β secretion on tumor progression. Cancer Cell 8: 349-350.
28. Kim, R., M. Emi, and K. Tanabe. 2006. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 119: 254-264.
29. Brown, R., A. Murray, B. Pope, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua. 2004. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β in patients with myeloma. Br. J. Hematol. 125: 743-748.
30. Beckebaum, S., X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati. 2004. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin. Cancer Res. 10: 7260-7269.
31. Li, M. O., Y. Y. Wan, S. Sanjabi, A. K. Robertson, and R. A. Flavell. 2006. Transforming growth factor-β regulation of immune responses. Annu. Rev. Immunol. 24: 99-146.
32. Marie, J. C, D. Liggitt, and A. Y. Rudensky. 2006. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-β receptor. Immunity 25: 441-454.
33. Li, M. O., S. Sanjabi, and R. A. Flavell. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471.
34. Cohen, S. B., P. D. Katsikis, M. Feldmann, and M. Londei. 1994. IL-10 enhances expression of the IL-2 receptor α chain on T cells. Immunology 83: 329-333.
35. Ho, A. S., and K. W. Moore. 1994. Interleukin-10 and its receptor. Ther. Immunol. I: 173-185.
36. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular en-dothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2: 1096-1103.
37. Sombroek, C. C., A. G. Stam, A. J. Masterson, S. M. Lougheed, M. J. Schakel, C. J. Meijer, H. M. Pinedo, A. J. van den Eertwegh, R. J. Scheper, and T. D. De Gruijl. 2002. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J. Immunol. 168: 4333-4343.
38. Yang, L., N. Yamagata, R. Yadav, S. Brandon, R. L. Courtney, J. D. Morrow, Y. Shyr, M. Boothby, S. Joyce, D. P. Carbone, and R. M. Breyer. 2003. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J. Clin. Invest. III: 727-735.
39. + cells producing nitric oxide. Cancer Res. 66: 11441-11446.